Mesothelioma Chemotherapy Treatment Improves Survival RateTreatment & Doctors
Asbestos.com is the nation’s most trusted mesothelioma resource
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
About The Mesothelioma Center at Asbestos.com
- Assisting mesothelioma patients and their loved ones since 2006.
- Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
- A+ rating from the Better Business Bureau.
- 5-star reviewed mesothelioma and support organization.
"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."LashawnMesothelioma patient’s daughter
How to Cite Asbestos.com’s Article
Whitmer, M. (2020, October 16). Mesothelioma Chemotherapy Treatment Improves Survival Rate. Asbestos.com. Retrieved October 4, 2022, from https://www.asbestos.com/news/2011/02/16/mesothelioma-chemotherapy-treatment-improves-survival-rate/
Whitmer, Michelle. "Mesothelioma Chemotherapy Treatment Improves Survival Rate." Asbestos.com, 16 Oct 2020, https://www.asbestos.com/news/2011/02/16/mesothelioma-chemotherapy-treatment-improves-survival-rate/.
Whitmer, Michelle. "Mesothelioma Chemotherapy Treatment Improves Survival Rate." Asbestos.com. Last modified October 16, 2020. https://www.asbestos.com/news/2011/02/16/mesothelioma-chemotherapy-treatment-improves-survival-rate/.
Mesothelioma is an aggressive and rare disease that affects the lining of several vital organs in the body. Almost exclusively caused by exposure to asbestos, mesothelioma affects 2,000 to 3,000 people each year in the United States.
Chemotherapy is considered one of the traditional forms of treatment, along with surgery and radiation.
Malignant peritoneal mesothelioma is the second most common form of the cancer and this form of the disease has shown improved response to chemotherapy in recent studies.
In an Australian study titled “Malignant Peritoneal Mesothelioma,” which tracked the epidemiology and new treatment advancements of peritoneal cancer, researchers detailed a chemotherapy treatment that combined the chemotherapeutic drugs pemetrexed and cisplatin. The study presented a median survival of 13 months and one-year survival of 66 percent in 66 patients. Patients (32) who received pemetrexed alone displayed a nine-month median survival and 0 percent one-year survival rate.
A new treatment study that showed very promising results utilizing a combination of cytoreductive surgery and intraperitoneal hyperthermic chemotherapy was conducted at the National Cancer Institute in Bethesda, Maryland. Using this treatment combination, 49 patients experienced a median survival of 92 months with a five-year survival rate of 59 percent. Other cancer hospitals recorded similar survival rates while utilizing these treatments.
While many treatment options have been of palliative nature in the past, new chemotherapy treatments for peritoneal cancer have given patients hope that some treatments may be curative. Due to the treatments being largely experimental, they can carry an enhanced risk of morbidity or mortality. However, the researchers in this study suggest that a combined treatment option may be the new standard of care.
New biomarkers discussed in this study helped doctors detect the disease in its earlier stages and lead to earlier treatment. Early detection has always been the key to effectively treating the disease and increasing the life expectancy of mesothelioma patients.